TNF and Crohn disease: In Crohn's disease, a combination of infliximab (anti-TNFα mAb) and natalizumab (anti-α4β1 mAb) resulted in enhanced efficacy with no difference in adverse events between the combination treatment group and those receiving infliximab alone (102).